29 , 30 These RNAi therapies showed a trend toward better clinical outcomes, including a lower rate of kidney stone events, an improvement in nephrocalcinosis, a better preservation of kidney function, and prevention of progression to kidney failure and systemic oxalosis. 30 However, both drugs were not successful in patients in whom systemic oxalosis already existed. 30 In this case, although the patient came in a progressive and late stage of systemic oxalosis, only 2 stone events were reported before.
← all excerpts
Spinal Cord Compression as the First Presentation of Primary Hyperoxaluria in a Patient With Kidney Failure: A Case Report and Literature Review.
1
—
—